per-transaction / unit sales with value-added services

Cost-plus / negotiated

3.6% Gross Margin (Thin (<20%))

transactional

Direct sales force and relationship-based; geographic focus by provider type or size

enterprise / institutional

pharmaceutical manufacturers / biotech

distributor / pharmaceutical wholesaler

services provider / consulting

Moderate

2.2% OpEx / Revenue (Highly Efficient)

Primarily domestic (U.S.) with significant international presence

Medium

Low

Yes

High

Moderate

Moderate

Partial

High

2.9% Return on Assets (Excellent)

Defensive

Moderate

5.09x Total Debt / Equity (High leverage)

Low intensity; China's 2023-2025 export-licensing regime on gallium, germanium, antimony, and rare-earth magnet materials — merely suspended for US-bound shipments until the November 2026 cliff, with licensing still in force — combined with advanced-node wafer fabrication concentrated in Taiwan, makes single-jurisdiction supply cutoff rather than commodity price the sector's binding 2026 chokepoint.

Sublinear

Moderate

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "17-0000 Architecture and Engineering Occupations", "23-0000 Legal Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations"]

0.34 (HIL — ~34% of characteristic roles agent-automatable)

Low intensity; commodities: silicon (polysilicon/wafers), copper, gold, aluminum, rare earth elements (NdPr magnets), gallium/germanium, tin (solder); geopolitical: China's 2023-2025 export-licensing regime on gallium, germanium, antimony, and rare-earth magnet materials — merely suspended for US-bound shipments until the November 2026 cliff, with licensing still in force — combined with advanced-node wafer fabrication concentrated in Taiwan, makes single-jurisdiction supply cutoff rather than commodity price the sector's binding 2026 chokepoint.

Medium burden; regimes: FTC, DOJ, GDPR, FCC, CFIUS, SEC; Antitrust breakup risk and cross-border data sovereignty rules are escalating.

0001140859

COR

0.2% CapEx / Revenue (Low-CapEx Asset-Light)

High

antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,churn_vulnerability_index,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,data_sovereignty_risk,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,marginal_cost_of_growth,monetization_vector,network_effect_present,pricing_architecture,pricing_power_rating,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,supply_chain_dependency,switching_cost_profile,vendor_lock_dependency_score

3

3

-5015

2026-09-16

2026-10-03T14:01|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m

0

2

none in window

per-transaction / unit sales with value-added services

Cost-plus / negotiated

3.6% Gross Margin (Thin (<20%))

transactional

Direct sales force and relationship-based; geographic focus by provider type or size

enterprise / institutional

pharmaceutical manufacturers / biotech

distributor / pharmaceutical wholesaler

services provider / consulting

Moderate

2.2% OpEx / Revenue (Highly Efficient)

Primarily domestic (U.S.) with significant international presence

Medium

Low

Yes

High

Moderate

Moderate

Partial

High

2.9% Return on Assets (Excellent)

Defensive

Moderate

5.09x Total Debt / Equity (High leverage)

Low intensity; China's 2023-2025 export-licensing regime on gallium, germanium, antimony, and rare-earth magnet materials — merely suspended for US-bound shipments until the November 2026 cliff, with licensing still in force — combined with advanced-node wafer fabrication concentrated in Taiwan, makes single-jurisdiction supply cutoff rather than commodity price the sector's binding 2026 chokepoint.

Sublinear

Moderate

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "17-0000 Architecture and Engineering Occupations", "23-0000 Legal Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations"]

0.34 (HIL — ~34% of characteristic roles agent-automatable)

Low intensity; commodities: silicon (polysilicon/wafers), copper, gold, aluminum, rare earth elements (NdPr magnets), gallium/germanium, tin (solder); geopolitical: China's 2023-2025 export-licensing regime on gallium, germanium, antimony, and rare-earth magnet materials — merely suspended for US-bound shipments until the November 2026 cliff, with licensing still in force — combined with advanced-node wafer fabrication concentrated in Taiwan, makes single-jurisdiction supply cutoff rather than commodity price the sector's binding 2026 chokepoint.

Medium burden; regimes: FTC, DOJ, GDPR, FCC, CFIUS, SEC; Antitrust breakup risk and cross-border data sovereignty rules are escalating.

0001140859

COR

0.2% CapEx / Revenue (Low-CapEx Asset-Light)

High

antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,churn_vulnerability_index,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,data_sovereignty_risk,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,marginal_cost_of_growth,monetization_vector,network_effect_present,pricing_architecture,pricing_power_rating,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,supply_chain_dependency,switching_cost_profile,vendor_lock_dependency_score

3

3

-5015

2026-09-16

2026-10-03T14:01|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m

0

2

none in window